This approval makes Eli Lillys oral GLP-1 receptor agonist, to be marketed as Foundayo, the second GLP-1 drug for weight loss available in pill form, after Wegovy, which gained approval in December 2025
However, none of this critical information is disclosed on the product website
Indeed, CNS glutamatergic neuron receptor populations, but not GABAergic neurons, are necessary for liraglutide-induced food intake and body weight reduction (71, 72)
Who should consider GLP-1 for weight loss
Recent Updates November 24, 2025: Updated Sheds treatment options to add Zepbound and remove Ozempic and Mounjaro
What the Research Says About Akkermansia Muciniphila and Inulin The brand describes Akkermansia muciniphila and artichoke-derived inulin as compounds studied in connection with gut and metabolic pathways, and that part of the marketing isn't invented - both are genuinely active subjects in gut-microbiome research